To a lesser extent, pharmacological inhibition of several critical PPIs has been explored as a targeted therapeutic approach for MLL1-r leukemia, as exemplified by KO-539, an inhibitor of the MLL1-Menin interaction, being in clinical trials [16]. Here, KMT2A is linked to leukemia.